title: Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
abstract: The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.
authors.affiliation: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Awais
authors.forename: Constantine S
authors.initials: CS
authors.lastname: Tam
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kontoyiannis
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000382:microbiology*; D019910:Mycobacterium marinum / Q000302:isolation & purification*; D012867:Skin / Q000382:microbiology / Q000473:pathology; D017192:Skin Diseases, Bacterial / Q000382:microbiology*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide